TWI875776B - 作為ｄ１正向異位調節劑之經取代的四氫異喹啉衍生物及其用途 - Google Patents

作為ｄ１正向異位調節劑之經取代的四氫異喹啉衍生物及其用途 Download PDF

Info

Publication number
TWI875776B
TWI875776B TW109122035A TW109122035A TWI875776B TW I875776 B TWI875776 B TW I875776B TW 109122035 A TW109122035 A TW 109122035A TW 109122035 A TW109122035 A TW 109122035A TW I875776 B TWI875776 B TW I875776B
Authority
TW
Taiwan
Prior art keywords
formula
compound
pharmaceutically acceptable
disease
acceptable salt
Prior art date
Application number
TW109122035A
Other languages
English (en)
Chinese (zh)
Other versions
TW202115010A (zh
Inventor
亞里 阿苔絲
大衛 斯考爾科
Original Assignee
比利時商優稀美生物醫藥股份有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 比利時商優稀美生物醫藥股份有限公司 filed Critical 比利時商優稀美生物醫藥股份有限公司
Publication of TW202115010A publication Critical patent/TW202115010A/zh
Application granted granted Critical
Publication of TWI875776B publication Critical patent/TWI875776B/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
    • C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07—Optical isomers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Anesthesiology (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
TW109122035A 2019-07-01 2020-06-30 作為ｄ１正向異位調節劑之經取代的四氫異喹啉衍生物及其用途 TWI875776B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19183643.6 2019-07-01
EP19183643 2019-07-01

Publications (2)

Publication Number Publication Date
TW202115010A TW202115010A (zh) 2021-04-16
TWI875776B true TWI875776B (zh) 2025-03-11

Family

ID=67137843

Family Applications (2)

Application Number Title Priority Date Filing Date
TW109122035A TWI875776B (zh) 2019-07-01 2020-06-30 作為ｄ１正向異位調節劑之經取代的四氫異喹啉衍生物及其用途
TW114104593A TW202537959A (zh) 2019-07-01 2020-06-30 製備四氫異喹啉衍生物之方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
TW114104593A TW202537959A (zh) 2019-07-01 2020-06-30 製備四氫異喹啉衍生物之方法

Country Status (23)

Country Link
US (1) US20220259179A1 (https=)
EP (1) EP3993794A1 (https=)
JP (1) JP7510444B2 (https=)
KR (1) KR20220029686A (https=)
CN (2) CN117700395A (https=)
AR (1) AR119318A1 (https=)
AU (1) AU2020299953B2 (https=)
BR (1) BR112021022378A2 (https=)
CA (1) CA3139571A1 (https=)
CL (1) CL2021002946A1 (https=)
CO (1) CO2021018155A2 (https=)
EC (1) ECSP21093559A (https=)
IL (2) IL289314B2 (https=)
MA (1) MA56440A (https=)
MX (2) MX2021015873A (https=)
MY (1) MY210361A (https=)
PE (1) PE20221020A1 (https=)
PH (1) PH12021552825A1 (https=)
SA (1) SA521431279B1 (https=)
SG (1) SG11202112537YA (https=)
TW (2) TWI875776B (https=)
WO (1) WO2021001288A1 (https=)
ZA (1) ZA202109193B (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2976784T3 (es) 2020-10-07 2024-08-08 Lilly Co Eli Derivados de fenil-3,4-dihidroisoquinolin-2(1H)-il-etan-1-ona como moduladores alostéricos positivos del receptor de dopamina D1
US20240083925A1 (en) 2020-12-18 2024-03-14 UCB Biopharma SRL Prodrugs of 2-(3,5-Dichloro-1-methyl-indazol-4-yl)-1-[(1S,3R)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1H-isoquinolin-2-yl]ethanone
JP7798891B2 (ja) 2020-12-18 2026-01-14 ユーシービー バイオファルマ エスアールエル Ｄ１陽性アロステリック調節因子としての置換テトラヒドロイソキノリン誘導体
WO2022129267A1 (en) * 2020-12-18 2022-06-23 UCB Biopharma SRL Amorphous solid dispersions
EP4304577A1 (en) * 2021-03-09 2024-01-17 Eli Lilly And Co. Use of mevidalen and other d1 positive allosteric modulators for slowing of parkinson's disease progression
WO2026022198A1 (en) 2024-07-25 2026-01-29 UCB Biopharma SRL Process for the preparation of 2-(3,5-dichloro-1-methyl-indazol-4-yl)-1-[(1 s,3 r)-3-(hydroxymethyl)-5-(1-hydroxy-1-methyl-ethyl)-1-methyl-3,4-dihydro-1 h-isoquinolin-2-yl]ethanone monohydrate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014193781A1 (en) * 2013-05-30 2014-12-04 Eli Lilly And Company 3,4-dihydroisoquinolin-2(1h)-yl compounds
WO2017178377A1 (en) * 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2679735A1 (en) 2007-03-01 2008-09-12 Janssen Pharmaceutica N.V. Tetrahydroisoquinoline compounds as modulators of the histamine h3 receptor
KR101284796B1 (ko) 2011-10-05 2013-07-10 (주)포인트엔지니어링 캔 패지키 타입의 광 디바이스 제조 방법 및 이에 의해 제조된 광 디바이스
WO2016055479A1 (en) 2014-10-08 2016-04-14 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives
TWI725408B (zh) 2018-04-20 2021-04-21 美商美國禮來大藥廠 多巴胺d1受體正向異位調節劑

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014193781A1 (en) * 2013-05-30 2014-12-04 Eli Lilly And Company 3,4-dihydroisoquinolin-2(1h)-yl compounds
WO2017178377A1 (en) * 2016-04-13 2017-10-19 Ucb Biopharma Sprl Tetrahydroisoquinoline derivatives

Also Published As

Publication number Publication date
CN113993857B (zh) 2024-01-02
CN117700395A (zh) 2024-03-15
SG11202112537YA (en) 2021-12-30
CL2021002946A1 (es) 2022-07-15
US20220259179A1 (en) 2022-08-18
WO2021001288A1 (en) 2021-01-07
IL289314A (en) 2022-02-01
MX2021015873A (es) 2022-02-03
IL289314B1 (en) 2025-05-01
AU2020299953A1 (en) 2022-01-06
AR119318A1 (es) 2021-12-09
PE20221020A1 (es) 2022-06-16
EP3993794A1 (en) 2022-05-11
JP2022539152A (ja) 2022-09-07
KR20220029686A (ko) 2022-03-08
MY210361A (en) 2025-09-13
ECSP21093559A (es) 2022-02-25
IL289314B2 (en) 2025-09-01
PH12021552825A1 (en) 2022-10-03
TW202115010A (zh) 2021-04-16
WO2021001288A9 (en) 2021-09-02
MX2024015493A (es) 2025-02-10
JP7510444B2 (ja) 2024-07-03
CA3139571A1 (en) 2021-01-07
MA56440A (fr) 2022-05-11
SA521431279B1 (ar) 2024-01-09
IL319939A (en) 2025-05-01
TW202537959A (zh) 2025-10-01
CN113993857A (zh) 2022-01-28
CO2021018155A2 (es) 2022-01-17
AU2020299953B2 (en) 2025-06-05
BR112021022378A2 (pt) 2022-03-08
ZA202109193B (en) 2023-11-29

Similar Documents

Publication Publication Date Title
TWI875776B (zh) 作為ｄ１正向異位調節劑之經取代的四氫異喹啉衍生物及其用途
JP7777589B2 (ja) ジヒドロイソキノリニル誘導体
TWI842923B (zh) 作為d1正向異位調節劑之經取代的四氫異喹啉衍生物
JP7798891B2 (ja) Ｄ１陽性アロステリック調節因子としての置換テトラヒドロイソキノリン誘導体
RU2824581C2 (ru) Замещенное производное тетрагидроизохинолина как позитивный аллостерический модулятор d1
JP2023551173A (ja) オクタヒドロイソキノリニル誘導体
HK40058931B (zh) 作为d1正变构调节剂的取代的四氢异喹啉衍生物
HK40058931A (en) A substituted tetrahydroisoquinoline derivative as a d1 positive allosteric modulator
HK40096273A (zh) 用作d1正向别构调节剂的经取代的四氢异喹啉衍生物